Literature DB >> 17098761

Septal ablation in hypertrophic obstructive cardiomyopathy improves systolic myocardial function in the lateral (free) wall: a follow-up study using CMR tissue tagging and 3D strain analysis.

Willem G van Dockum1, Joost P A Kuijer, Marco J W Götte, Folkert J Ten Cate, Jurrien M Ten Berg, Aernout M Beek, Jos W R Twisk, Johannes Tim Marcus, Cees A Visser, Albert C van Rossum.   

Abstract

AIMS: Alcohol septal ablation (ASA) has been successful in the treatment of symptomatic hypertrophic obstructive cardiomyopathy (HOCM). The aim of this study is to evaluate the effects of ethanol-induced myocardial infarcts on regional myocardial function using cardiac magnetic resonance (CMR) tissue tagging and 3-dimensional (3D) strain analysis. METHODS AND
RESULTS: In nine patients (age 52+/-15 years) who underwent ASA, CMR was performed prior to and 6 months after the procedure. Regional myocardial mass was evaluated using cine imaging. Myocardial tagging was used to calculate systolic 3D myocardial strain values. These strain values were used to calculate the shortening index (SI), a robust parameter for myocardial contraction. Maximum end-systolic (ES) SI and systolic SI rate were quantified in three circumferential segments: septum, adjacent, and remote (lateral) myocardium. Compared with baseline, septal and non-septal mass decreased at follow-up (from 72+/-27 to 59+/-21 g; P=0.008 and from 131+/-34 to 109+/-30 g; P=0.008, respectively). In the septum, maximum ES SI and SI rate remained unchanged after ASA. In adjacent myocardium, ES SI remained unchanged, whereas SI rate improved (from -56.5+/-21.1 to -70.0+/-16.7%/s; P=0.02). Both ES SI and SI rate improved significantly in remote myocardium (from -16.9+/-2.8 to -18.8+/-3.2%; P=0.02 and from -70.3+/-9.2 to -86.1+/-15.0%/s; P=0.01, respectively).
CONCLUSION: Reduction of left ventricular (LV) outflow tract obstruction in symptomatic HOCM is associated with a significant reduction in myocardial mass and improvement of intramural systolic function in the lateral (remote) wall, indicating reversed LV remodelling.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17098761     DOI: 10.1093/eurheartj/ehl358

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  12 in total

1.  Evaluation of hypertrophic cardiomyopathy: new horizons for CMR?

Authors:  E E van der Wall; H M Siebelink; J J Bax
Journal:  Neth Heart J       Date:  2010-03       Impact factor: 2.380

2.  The risk of non-sustained ventricular tachycardia after percutaneous alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy.

Authors:  Mariusz Klopotowski; Lidia Chojnowska; Lukasz A Malek; Renata Maczynska; Krzysztof Kukula; Marcin Demkow; Adam Witkowski; Maciej Dabrowski; Maciej Karcz; Rafal Baranowski; Beata Kusmierczyk-Droszcz; Mariusz Kruk; Jacek Jamiolkowski; Mariusz Kusmierczyk; Lukasz Szumowski; Witold Ruzyllo
Journal:  Clin Res Cardiol       Date:  2010-02-11       Impact factor: 5.460

3.  Maturation of Lesions Induced by Myocardial Cavitation-Enabled Therapy.

Authors:  Xiaofang Lu; Douglas L Miller; Chunyan Dou; Yiying I Zhu; Mario L Fabiilli; Gabe E Owens; Oliver D Kripfgans
Journal:  Ultrasound Med Biol       Date:  2016-04-14       Impact factor: 2.998

4.  Peak systolic longitudinal strain of the lateral left ventricular wall improves after septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: a follow-up study using speckle tracking echocardiography.

Authors:  Lothar Faber; Christian Prinz; Dirk Welge; Detlef Hering; Thomas Butz; Olaf Oldenburg; Nicola Bogunovic; Dieter Horstkotte
Journal:  Int J Cardiovasc Imaging       Date:  2010-08-08       Impact factor: 2.357

Review 5.  Evaluation of left ventricular function, rotation, twist and untwist in patients with hypertrophic cardiomyopathy.

Authors:  Xue-Wei He; Ze-Zhou Song
Journal:  Exp Clin Cardiol       Date:  2013

6.  Determinants of myocardial energetics and efficiency in symptomatic hypertrophic cardiomyopathy.

Authors:  Stefan A J Timmer; Tjeerd Germans; Marco J W Götte; Iris K Rüssel; Pieter A Dijkmans; Mark Lubberink; Jurrien M ten Berg; Folkert J ten Cate; Adriaan A Lammertsma; Paul Knaapen; Albert C van Rossum
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01-13       Impact factor: 9.236

Review 7.  Safety and efficacy of the remote magnetic navigation for ablation of ventricular tachycardias--a systematic review.

Authors:  Ferdi Akca; Ibrahim Önsesveren; Luc Jordaens; Tamas Szili-Torok
Journal:  J Interv Card Electrophysiol       Date:  2011-12-20       Impact factor: 1.900

8.  Evaluation of myocardial glucose metabolism in hypertrophic cardiomyopathy using 18F-fluorodeoxyglucose positron emission tomography.

Authors:  Rie Aoyama; Hitoshi Takano; Yasuhiro Kobayashi; Mitsunobu Kitamura; Kuniya Asai; Yasuo Amano; Shin-Ichiro Kumita; Wataru Shimizu
Journal:  PLoS One       Date:  2017-11-27       Impact factor: 3.240

9.  Alcohol septal ablation for hypertrophic obstructive cardiomyopathy.

Authors:  Hicham El Masry; Jeffrey A Breall
Journal:  Curr Cardiol Rev       Date:  2008-08

10.  Cardiac MR Imaging of Hypertrophic Cardiomyopathy: Techniques, Findings, and Clinical Relevance.

Authors:  Yasuo Amano; Mitsunobu Kitamura; Hitoshi Takano; Fumi Yanagisawa; Masaki Tachi; Yasuyuki Suzuki; Shinichiro Kumita; Morimasa Takayama
Journal:  Magn Reson Med Sci       Date:  2018-01-18       Impact factor: 2.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.